What is Upstream Bio?
Upstream Bio is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory diseases. The company's lead program targets the TSLP receptor, a validated target upstream of multiple signaling cascades implicated in both common and rare diseases. By inhibiting TSLP, Upstream Bio aims to conquer inflammation at its source, potentially offering new treatment avenues for a wide range of immune-related conditions.
How much funding has Upstream Bio raised?
Upstream Bio has raised a total of $2.5B across 3 funding rounds:
Series A
$2B
Series B
$200M
Stock Offering
$255M
Series A (2022): $2B with participation from Decheng Capital, OrbiMed, access-biotechnology.com, and Maruho
Series B (2023): $200M led by Bain Capital, OrbiMed, and Enavate Sciences
Stock Issuance/Offering (2024): $255M, investors not publicly disclosed
Key Investors in Upstream Bio
Bain Capital
Bain Capital is a leading global private investment firm with a broad focus across Private Equity, Growth & Venture, and Capital Solutions. Their Special Situations team offers flexible funding tailored to specific company needs, supported by operational and strategic value-add services.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm dedicated to the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health. They provide investment and strategic support to companies at various stages of development.
Decheng Capital
Decheng Capital is a global investment firm focused on early-stage life science and growth-stage healthcare companies. They aim to build leading companies by leveraging revolutionary technologies and strong market presence.
What's next for Upstream Bio?
The substantial enterprise-level funding, including a recent major strategic investment, positions Upstream Bio for accelerated growth and clinical development. This capital infusion is expected to fuel the advancement of its TSLP receptor inhibitor through clinical trials, expand its research capabilities, and potentially broaden its pipeline to address a wider spectrum of inflammatory and immune-mediated diseases. The company's strategic focus on upstream targets suggests a forward-thinking approach to therapeutic innovation.
See full Upstream Bio company page
